2024 HCPCS Code C9783
Blinded procedure for transcatheter implantation of coronary sinus reduction device or placebo control, including vascular access and closure, right heart catherization, venous and coronary sinus angiography, imaging guidance and supervision and interpretation when performed in an approved investigational device exemption (ide) study
TAGS: sinus interpretation performed coronary transcatheter placebo vascular reduction imaging procedure implantation heart study guidance exemption approved venous blinded supervision device investigational access right
Short Description | Blind cor sinus reducer impl |
HCPCS Coverage Code | D - Special coverage instructions apply |
HCPCS Action Code | N - No maintenance for this code |
HCPCS Action Effective Date | April 01, 2022 |
HCPCS Code Added Date | April 01, 2022 |
HCPCS Pricing Indicator Code | 53 - Statute |
HCPCS Multiple Pricing Indicator Code | A - Not applicable as HCPCS priced under one methodology |
HCPCS Coverage Issues Manual Reference Section Number | |
HCPCS Type Of Service Code | 2 - Surgery |
HCPCS Anesthesia Base Unit Quantity | 0 |
Check Similar HCPCS Codes
- C9055 - Inj, brexanolone
- C9056 - Injection, givosiran
- C9057 - Inj cetirizine hydrochloride
- C9058 - Injection,pegfilgrastim-bmez
- C9059 - Injection, meloxicam
- C9060 - Fluoroestradiol f18
- C9061 - Injection, teprotumumab-trbw
- C9062 - Daratumumab hyaluronidase
- C9063 - Injection, eptinezumab-jjmr
- C9064 - Mitomycin pyelocalyceal inst
- C9065 - Romidepsin non-lyophilized
- C9066 - Sacituzumab govitecan-hziy
- C9067 - Gallium ga-68 dotatoc
- C9068 - Copper cu-64, dotatate, dx
- C9069 - Belantamab mafodontin-blmf
- C9070 - Injection, tafasitamab-cxix
- C9071 - Injection, viltolarsen
- C9072 - Inj, imm glob asceniv
- C9073 - Brexucabtagene autoleucel ca
- C9074 - Injection, lumasiran